James Randolph Hillard
Chairman at Phase 2 Discovery, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ronald Brown | M | 70 |
University of Cincinnati (Ohio)
| 11 years |
J. Schlotman | M | 66 |
University of Cincinnati (Ohio)
| - |
Tao Sheng Huang | M | 62 |
University of Cincinnati (Ohio)
| - |
Robert Ludke | M | - |
University of Cincinnati (Ohio)
| - |
Ihab M. Hamdi Saad | M | - |
University of Cincinnati (Ohio)
| - |
Santa Ono | M | - |
University of Cincinnati (Ohio)
| - |
Awatef Hamed | M | - |
University of Cincinnati (Ohio)
| - |
Daniel Acosta | M | - |
University of Cincinnati (Ohio)
| - |
Hagit Limor Sunberg | F | - |
University of Cincinnati (Ohio)
| - |
Jason Charles Heikenfeld | M | - |
University of Cincinnati (Ohio)
| - |
Daniel von Allmen | M | - |
University of Cincinnati (Ohio)
| 15 years |
Don Wathen | M | - |
University of Cincinnati (Ohio)
| 13 years |
William H. Wilson | M | - |
University of Cincinnati (Ohio)
| - |
Bob Arkeilpane | M | - |
University of Cincinnati (Ohio)
| - |
Bogdan Vykhovanyuk | M | - |
University of Cincinnati (Ohio)
| - |
Marianne Lewis | F | - |
University of Cincinnati (Ohio)
| - |
Timothy Jachna | M | - |
University of Cincinnati (Ohio)
| - |
Melanie Kroger-Jarvis | F | - |
University of Cincinnati (Ohio)
| - |
Alberto Jones | M | - |
University of Cincinnati (Ohio)
| - |
Valerio Ferme | M | - |
University of Cincinnati (Ohio)
| - |
Carl Dieso | M | - |
University of Cincinnati (Ohio)
| - |
Victor E. Schwartz | M | - |
University of Cincinnati (Ohio)
| - |
Stephanie Parrish | F | - |
University of Cincinnati (Ohio)
| - |
Glenn Grismere | M | - |
University of Cincinnati (Ohio)
| - |
Thomas Finn | M | 63 |
University of Cincinnati (Ohio)
| - |
Joseph A. Steger | M | 87 |
University of Cincinnati (Ohio)
| - |
Phillip Cox | M | 76 |
University of Cincinnati (Ohio)
| - |
George Schaefer | M | 78 |
University of Cincinnati (Ohio)
| - |
Mark R. White | M | - |
University of Cincinnati (Ohio)
| - |
Robert Jerome Chapman | M | 77 |
University of Cincinnati (Ohio)
| - |
John B. Harley | M | 74 |
University of Cincinnati (Ohio)
| 14 years |
Frederick Russ | M | 79 |
University of Cincinnati (Ohio)
| 35 years |
Karl Scheer | M | - |
University of Cincinnati (Ohio)
| 13 years |
Richard C. Levy | M | 77 |
University of Cincinnati (Ohio)
| 40 years |
Timothy Johnson | M | 81 |
University of Cincinnati (Ohio)
| 54 years |
Salvatore Privitera | M | 57 |
University of Cincinnati (Ohio)
| - |
Ronald A. Khan | M | - |
University of Cincinnati (Ohio)
| - |
Frank P. Zemlan | M | - |
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | - |
Thomas D. Geracioti | M | - |
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | - |
John M. Tew | M | - |
University of Cincinnati (Ohio)
| - |
Andrew Robell | M | - |
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | - |
James Jeffery Mulchahey | M | - |
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | - |
Eli M. Roth | M | - |
University of Cincinnati (Ohio)
| - |
James Holloman | M | 69 |
University of Cincinnati (Ohio)
| - |
Peter Disimile | M | - |
University of Cincinnati (Ohio)
| - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 45 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Randolph Hillard
- Personal Network